LA JOLLA, Calif., Sept. 13, 2022 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market MNOV and JASDAQ Market of the Tokyo Stock Exchange (code number: 4875) announced today that they have received a Notice of Acceptance from the Canadian Intellectual Property Office for a pending patent application covering MN-001 (tipelukast) and MN-002 (a major metabolite of MN- 001) for the treatment of hypertriglyceridemia, hypercholesterolemia and hyperlipoproteinemia.

Once granted, the patent maturing on this allowable patent application is not expected to expire until July 2034 at the earliest. The allowable claims include the use of MN-001 or MN-002 to lower a blood level of triglycerides, to lower a blood level of total cholesterol, and to reduce a blood level of low-density lipoprotein (LDL). Permitted claims include oral administration including liquid and solid dosage forms. Acceptable claims cover a wide range of doses and a number of different dosing frequencies.

Kazuko Matsuda, MD Ph.D, MPH., Chief Medical Officer, MediciNova, Inc., commented, “We are very pleased to be informed that this new patent has been granted. As we already have patents for similar indications in the US, we believe this additional patent in Canada could increase the potential value of MN-001 in Europe, Japan, China and Korea. In our Phase 2 study, into patients with NASH or NAFLD with hypertriglyceridemia, MN-001 demonstrated a statistically significant reduction in the value of MN-001 mean serum triglycerides after only 8 weeks of treatment.”

About MN-001 (tipelukast)

MN-001 (Tipelukast) is a novel, orally administered, small molecule compound with multiple mechanisms of action that is in clinical development for the treatment of chronic inflammatory and fibrotic diseases, among others, due to its anti-inflammatory and anti-fibrotic properties. Based on the finding that MN-001 (Tipelukast) reduces blood triglycerides (TG) from our previous…